Even after a flurry of corporate updates during the first two days of the J.P. Morgan Healthcare Conference, many more ...

“Despite industry challenges, Samsung Biologics is well positioned to kick-start a new phase of growth in 2025 with the ...

As the J.P. Morgan Healthcare Conference enters its second day, we're tracking presentations from GSK, Novartis, Sanofi, Eli ...

Unfortunately for the company, however, the early glimpse at its fourth-quarter performance doesn’t seem to be going over ...

The anti-vaccine movement in the U.S. has gained momentum with President-elect Donald Trump's nomination of Robert F. Kennedy ...

After Regeneron Chief Scientific Officer George Yancopoulos, M.D., Ph.D., spent more than 25 minutes waxing about the company ...

Monday, three Big Pharma leaders took center stage and addressed concerns about future patent expirations head-on.

Welcome to day 1 of the J.P. Morgan Healthcare Conference, the industry's most significant dealmaking event each year.  | For ...

At $132 per share, J&J paid a 39% premium on Friday’s closing price of Intra-Cellular, a New York City based biotech that ...

Less than two months after scoring what analysts deemed a "best-case" FDA approval for its cardiomyopathy drug Attruby, ...

Stéphane Bancel, CEO of mRNA specialist Moderna, delivered some difficult truths to shareholders about the company’s ...

At the start of each of the last five years, the share price of Alkermes has increased. It’s the kind of steady trajectory ...